KCNJ8
MOLECULAR TARGETpotassium inwardly-rectifying channel, subfamily J, member 8
KCNJ8 (potassium inwardly-rectifying channel, subfamily J, member 8) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KCNJ8
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Cromakalim | 2.08 | 7 |
| 2 | Adenosine Triphosphate | 0.69 | 1 |
| 3 | Glyburide | 0.69 | 1 |
| 4 | Guanosine Diphosphate | 0.69 | 1 |
| 5 | Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). | 0.69 | 1 |
| 6 | Nicorandil | 0.69 | 1 |
| 7 | Tolbutamide | 0.69 | 1 |
| 8 | Uridine Diphosphate | 0.69 | 1 |
About KCNJ8 as a Drug Target
KCNJ8 (potassium inwardly-rectifying channel, subfamily J, member 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented KCNJ8 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KCNJ8 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.